Amlitelimab is effective at improving moderate to severe AD across all body regions, including the difficult-to-treat head and neck region.

A new study published in the journal of Pediatric Dermatology revealed that treatment with dupilumab achieved effective ...

What exactly is severe AD? AD is the most common type of eczema. When this eczema becomes severe, a person has patches of skin that are red, swollen, and unbearably itchy. The patches of AD can weep ...

Atopic dermatitis (AD) is a chronic disease that affects an increasing number of children and adults. The skin is dry and ...

Rocatinlimab, targeting the OX40 pathway, shows significant efficacy in moderate to severe atopic dermatitis, marking a new therapeutic class in disease management. Long-term melanoma data reveal ...

Oncodermatology is evolving with nonsurgical approaches and immune checkpoint inhibitors, improving outcomes in aggressive ...

A new study published in the Journal of the European Academy of Dermatology and Venerology showed that nemolizumab, an ...

Among patients with moderate to severe atopic dermatitis, atopic comorbidities did not change the benefits seen with lebrikizumab, according to data published in Annals of Allergy, Asthma & Immunology ...

If you have atopic dermatitis, a skin condition commonly known as eczema, prescription creams or other topical medicines and moisturizers are usually enough to manage it. However, if your eczema is ...

On Saturday, February 14, 2025, from 10am to 1pm and from 3pm to 5pm, in Piazza Garibaldi in Naples, the Dermatology Department of Federico II will provide an excellent team of experts in ...